The Government on Tuesday approved the amendments of certain provisions contained in the policy guidelines on the expansion of FM radio broadcasting services through private agencies (Phase-III) referred to as Private FM Phase-III Policy Guidelines. New Delhi:  The Government on Tuesday approved the amendments of certain provisions contained in the... The post appeared first on .

The Government on Tuesday approved the amendments of certain provisions contained in the policy guidelines on the expansion of FM radio broadcasting services through private agencies (Phase-III) referred to as Private FM Phase-III Policy Guidelines. New Delhi:  The Government on Tuesday approved the amendments of certain provisions contained in the... The post appeared first on .

New Delhi [India], October 4 (ANI): The Government on Tuesday approved the amendments of certain provisions contained in the policy guidelines on the expansion of FM radio broadcasting services through private agencies (Phase-III) referred to as Private FM Phase-III Policy Guidelines.

New Delhi [India], August 10 (ANI): Union Health Secretary Rajesh Bhushan on Wednesday said that the Centre has approved Biological E's Corbevax as a precaution dose after completion of six months from the date of administration of the second dose of either Covaxin or Covishield vaccines for the population above 18 years.

New Delhi [India], August 7 (ANI): The second phase of the Common University Entrance Test for Undergraduates (CUET-UG) is now scheduled to be conducted between August 24 to 28 and a new Admit Card will be issued before the exam, UGC chairman Mamidala Jagadesh Kumar informed on Sunday.

Pune (Maharashtra) [India], June 29 (ANI): India's first indigenously developed mRNA vaccine against the COVID-19 gets the Emergency Use Authorization (EUA), to be sold under the brand name GEMCOVAC™-19 and will be rolled out soon, informed the officials on Wednesday.

New Delhi [India], May 22 (ANI): Delhi Police busted an IPL betting racket in Chander Vihar, Phase-III, Nihal Vihar on Sunday and arrested six persons engaged in it.

New Delhi Feb 21 PTI Translational Health Science and Technology Institute THSTI an autonomous body under the Department of Biotechnology and Panacea Biotec are developing a vaccine that would offer broad protection against SARS-CoV-2 variants and other betacoronaviruses with financial support from the Coalition for Epidemic Preparedness Innovations CEPI CEPI will provide funding of up to USD 125 million to support the development of multi-epitope nanoparticle-based vaccine candidates and advance the manufacturing process a CEPI statement said It added that through this research programme THSTI and Panacea Biotec will design and select the lead antigen through proof-of-concept preclinical studies and undertake initial clinical development through Phase III studies as they seek to establish clinical proof of concept for novel vaccine candidates to provide broad protection against MERS SARS-CoV SARS-CoV-2 and its variants We are honoured to collaborate with CEPI and THSTI for development of a betacoronavirus vaccine that can provide broad protection against SARS-COV-2 and other coronaviruses Rajesh Jain Managing Director of Panacea Biotec said Richard Hatchett CEO of CEPI noted that over the past two years coronaviruses have demonstrated their pandemic potential with devastating effect Its therefore vital for global health security that we invest now in research to develop vaccines that are broadly protective against variants of SARS-CoV-2 and other coronaviruses before they emerge Hatchett said Pramod Kumar Garg Executive Director of the Translational Health Science and Technology Institute said he looked forward to a fruitful academia-industry collaboration with Panacea Biotec in bringing out a vaccine product for global public health We are hopeful that this collaboration will further enhance our capabilities to develop a robust platform and pipeline for development of products against other infectious diseases Garg said PTI SKU SMN

New Delhi Feb 21 PTI Work under the Yamuna Action Plan Phase III has been set back by up to two years due to delays in permissions from agencies the lockdown and a temporary ban on construction activities to counter high pollution levels according to a Delhi Jal Board reportIn the report detailing work progress till January 2022 the Delhi Jal Board DJB said the work was delayed due to a delay in tree-cutting permission nod from road-owning agencies traffic permissions EPCA ban and slow progress during the monsoon seasonThe DJB is the project executing agency for the Yamuna Action Plan Phase III aimed at reducing the pollution load in the river in Delhi by treating domestic waste water for which the Centre received funding from the Japan International Cooperation Agency JICA in 2011To reduce pollution in the Yamuna YAP III is augmenting sewage treatment capacity with the renovation rehabilitation and replacement of the existing sewerage system the report saidThe project focuses on rehabilitation of trunk sewers rising mains and existing waste water treatment plants improving the treated effluent quality to tertiary level construction of a new waste water treatment plant at Okhla and instructional strengthening and capacity buildingThe project components fall in three drainage zones Okhla Kondli and RithalaAccording to the report the rehabilitation of trunk sewer number 4 and Nawana Road Anand Vihar Hargovind Enclave and Vikas Marg sewers which started on November 29 2017 and was to be completed in November 2019 is now likely to be completed on February 28 2022Work was delayed due to delay in permission from road-owning agencies traffic permissions at Vikas Marg and Narwana Road EPCA ban in 2019 complete lockdown from March 22 to May 18 in 2020 and again from April 19 to May 31 in 2021 due to COVID-19 No work at site from July 1 to September 30 in rainy season as per the directions from DJB authority the report readThe rehabilitation and upgradation of the Rithala Phase 1 waste water treatment plant of 40 MGD million gallons a day capacity to meet the new standards of effluents BOD 10 milligram per litre and total dissolved solids 10 mg per litre was to be completed by December 14 2021 It is now likely to be completed by December 31 2022Work was delayed due to delay in tree cutting permission EPCA ban complete lockdowns due to COVID-19 and slow progress during the monsoon season the report read adding only 549 per cent of the work has been completedThe rehabilitation and upgradation of Kondli Phase 1 10 MGD Phase 2 25 MGD and Phase 3 10 MGD WWTPs to meet the new standards of effluents should have ended on February 9 2022 but it has been delayed till the end of this yearThe laying of rising and pumping mains at various locations in the Kondli WWTP catchment area which started in July 2018 was scheduled to be completed in two years However the construction agency could only complete it in December 2021Work was delayed due to delay in permission from road owning agencies DDA horticulture department traffic police railways and resistance from local residents the report saidThe 22-kilometre stretch of the Yamuna between Wazirabad and Okhla which is less than two percent of its length of 1370 kilometres from Yamunotri to Allahabad accounts for around 80 per cent of the pollution load in the riverUntapped waste water from unauthorised colonies and jhuggi-jhopri clusters and poor quality of treated waste water discharged from WWTPs is the main reason behind high levels of pollution in the riverDelhi generates around 720 million gallons of waste water a day The 35 STPs located at 20 locations across Delhi can treat up to 597 MGD of sewage and have been utilising around 90 per cent of their capacityOn an average 24 out of the 35 STPs in the national capital did not meet the prescribed standards for waste water over the last one year according to government dataOf the 13 common effluent treatment plants in industrial areas across Delhi only six comply with the DPCC standards for waste water on an average PTI GVS IJT

New Delhi [India], January 17 (ANI): The testing of Gennova Biopharmaceutical's mRNA vaccine for the Omicron variant of COVID-19 is subject to regulatory approvals, the company's official spokesperson informed on Monday.